Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.
Journal: Science translational medicine
Published: July 29, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026
A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.
Journal: Haematologica
Published: February 05, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 30, 2026
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.
Journal: Cancer
Published: January 16, 2026
Robust CD4+ CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Journal: Blood cancer journal
Published: October 13, 2025
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Journal: Nature medicine
Published: October 03, 2025
Last Updated: 09/26/2026